Activated PPARd Protects from Senescence Figure 2. L-165041 prevents both senescence and apoptosis induced by doxorubicin. Pre-treatment with the PPARd agonist L-165041 (L- 165) prevents both senescence induced by low (0.1 mM) doses of doxorubicin (Dox) (A,B,C), and apoptosis induced by high (1 mM) doses of Dox (E) in neonatal rat cardiomyocytes. (A) Percentage of SA-b-gal positive cells 3 days after treatment. *p,0.05 versus control (ct), 1p,0.05 versus Dox 0.1. (B) Cell size, 3 and 5 days after treatment. *p,0.05 versus ct, 1p,0.05 versus Dox 0.1. (C) Photographs showing cells (from top to bottom): SA-b-gal activity evaluated 3 days after treatment with Dox 0.1 (magnification, 6200), F-actin density (magnification, 6400), and AV/PI staining evaluated 24 h PLOS ONE | www.plosone.org 4 September 2012 | Volume 7 | Issue 9 | e46126